Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CG223
- Development stage
- Preclinical
- Lead developer
- ConverGene
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
CG223 is a small molecule dual inhibitor that targets both BET bromodomains (specifically BRD4) and the dopamine receptor D2 (DRD2). Developed by ConverGene as the lead candidate in their CVG101 program, CG223 is designed to address the complex signaling pathways in solid tumors and hematologic malignancies, including acute myeloid leukemia (AML). By simultaneously inhibiting epigenetic readers and G-protein coupled receptor signaling, the compound aims to overcome resistance mechanisms common in monotherapies. As of 2024, CG223 has progressed to IND-enabling studies and pre-clinical toxicology testing.
- Other names
- CG223/CG250
02
Targets
BRD3 (Bromodomain-containing protein 3)BRD4 (Bromodomain-containing protein 4)BRDT (Bromodomain testis-specific protein)DRD2 (Dopamine D2 Receptor)
Beyond the preview
Go deeper on CG223.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CG223.